Mark N Maxwell

US Patent:

7927872, Apr 19, 2011

Filed:

Jun 20, 2005

Appl. No.:

11/628487

Inventors:

Mark E. Maxwell - Lansdale PA, US
Michael Martin Ollmann - Redwood City CA, US
Timothy S. Heuer - El Granada CA, US
Benjamin C. Hitz - San Francisco CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

C12N 5/00
C12Q 1/42

US Classification:

435375, 435 21, 435 6, 435 7, 435 18, 435 71, 536 232

Abstract:

Human ALDO genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of ALDO are provided.

US Patent:

20040142888, Jul 22, 2004

Filed:

Aug 7, 2003

Appl. No.:

10/638225

Inventors:

Veeraswamy Manne - Philadelphia PA, US
Mark Lynch - Madison CT, US
Petra Ross-MacDonald - Pennington NJ, US
Terry Stouch - West Windsor NJ, US
Naomi Laing - Stoneham MA, US
Pamela Carroll - Princeton NJ, US
Kevin Fitzgerald - Lambertville NJ, US
Louis Lombardo - Belle Mead NJ, US
Michael Costa - San Francisco CA, US
Mark Maxwell - San Francisco CA, US
Rachel Kindt - San Carlos CA, US
Mark Lackner - Brisbane CA, US
Tak Hung - Foster City CA, US
Carol O'Brian - Castro Valley CA, US
Hai Zhang - El Sobrante CA, US
Katherine Brown - San Francisco CA, US
Jae Lee - Cupertino CA, US

International Classification:

A61K048/00
G01N033/574
A61K031/5513
A61K031/47

US Classification:

514/044000, 514/221000, 514/310000, 435/007230

Abstract:

The present invention provides methods for inducing apoptosis in a cell, the methods generally involving contacting the cell with an agent that reduces the level and/or activity of RabGGT. The present invention further provides methods for treating a disorder related to unwanted cell proliferation in an individual, the methods generally involving administering to the individual an agent that reduces the level and/or activity of RabGGT. The present invention further provides methods for reducing apoptosis in a cell, the methods generally involving increasing the level and/or activity of RabGGT in the cell. The present invention further provides methods for treating disorders associated with excessive apoptosis. The present invention further provides methods for identifying a cell that is amenable to treatment with the methods of the present invention. The present invention further provides methods for modulating a binding event between RabGGT and a RabGGT interacting protein. The present invention further provides a 3-dimensional structure of RabGGT, and methods of use of the structure to identify compounds that modulate RabGGT activity.

US Patent:

20080095763, Apr 24, 2008

Filed:

Jun 20, 2005

Appl. No.:

11/628636

Inventors:

Mark Maxwell - Lansdale PA, US
Michael Ollmann - Redwood City CA, US
Timothy Heuer - El Granada CA, US
Lynn Bjerke - Surrey, GB

Assignee:

EXELIXIS, INC. - South San Francisco CA

International Classification:

C12N 5/06
A01K 67/00
A61K 31/70
C12Q 1/02
C12Q 1/68
G01N 33/53
C12Q 1/48
A61K 39/395
A61P 43/00

US Classification:

424130100, 435015000, 435029000, 435375000, 435006000, 435007100, 514044000, 800003000

Abstract:

Human CDK9 genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF, comprising screening for agents that modulate the activity of CDK9 are provided.

US Patent:

20090053239, Feb 26, 2009

Filed:

Jun 20, 2005

Appl. No.:

11/628575

Inventors:

Mark E. Maxwell - Lansdale PA, US
Michael Martin Ollmann - Redwood City CA, US
Timothy S. Heuer - El Granada CA, US
Lynn Margaret Bjerke - Surrey, GB

Assignee:

EXELIXIS, INC. - San Francisco CA

International Classification:

A61K 39/395
G01N 33/00
C12Q 1/02
G01N 33/566
A61P 31/00
C12Q 1/68
A01K 67/027
C12N 5/06

US Classification:

4241721, 436 94, 436 86, 435 29, 436501, 435 6, 800 3, 435375

Abstract:

Human MPTEN genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of MPTEN are provided.